Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 87

1.

Intravital microscopy of collective invasion plasticity in breast cancer.

Ilina O, Campanello L, Gritsenko PG, Vullings M, Wang C, Bult P, Losert W, Friedl P.

Dis Model Mech. 2018 Jul 11. pii: dmm.034330. doi: 10.1242/dmm.034330. [Epub ahead of print]

2.

Whole-Slide Mitosis Detection in H&E Breast Histology Using PHH3 as a Reference to Train Distilled Stain-Invariant Convolutional Networks.

Tellez D, Balkenhol M, Otte-Holler I, van de Loo R, Vogels R, Bult P, Wauters C, Vreuls W, Mol S, Karssemeijer N, Litjens G, van der Laak J, Ciompi F.

IEEE Trans Med Imaging. 2018 Mar 28. doi: 10.1109/TMI.2018.2820199. [Epub ahead of print]

PMID:
29994086
3.

1399 H&E-stained sentinel lymph node sections of breast cancer patients: the CAMELYON dataset.

Litjens G, Bandi P, Ehteshami Bejnordi B, Geessink O, Balkenhol M, Bult P, Halilovic A, Hermsen M, van de Loo R, Vogels R, Manson QF, Stathonikos N, Baidoshvili A, van Diest P, Wauters C, van Dijk M, van der Laak J.

Gigascience. 2018 Jun 1;7(6). doi: 10.1093/gigascience/giy065.

4.

Vulvar cancer: Two pathways with different localization and prognosis.

Hinten F, Molijn A, Eckhardt L, Massuger LFAG, Quint W, Bult P, Bulten J, Melchers WJG, de Hullu JA.

Gynecol Oncol. 2018 May;149(2):310-317. doi: 10.1016/j.ygyno.2018.03.003. Epub 2018 Mar 16.

PMID:
29555332
5.

Assessment of HER2 status in breast cancer biopsies is not affected by accelerated tissue processing.

Bulte JP, Halilovic A, Kalkman S, van Cleef PHJ, van Diest PJ, Strobbe LJA, de Wilt JHW, Bult P.

Histopathology. 2018 Jul;73(1):81-89. doi: 10.1111/his.13507. Epub 2018 Apr 24.

PMID:
29495112
6.

Characterizing steroid hormone receptor chromatin binding landscapes in male and female breast cancer.

Severson TM, Kim Y, Joosten SEP, Schuurman K, van der Groep P, Moelans CB, Ter Hoeve ND, Manson QF, Martens JW, van Deurzen CHM, Barbe E, Hedenfalk I, Bult P, Smit VTHBM, Linn SC, van Diest PJ, Wessels L, Zwart W.

Nat Commun. 2018 Feb 2;9(1):482. doi: 10.1038/s41467-018-02856-2.

7.

The frequency of missed breast cancers in women participating in a high-risk MRI screening program.

Vreemann S, Gubern-Merida A, Lardenoije S, Bult P, Karssemeijer N, Pinker K, Mann RM.

Breast Cancer Res Treat. 2018 Jun;169(2):323-331. doi: 10.1007/s10549-018-4688-z. Epub 2018 Jan 31.

8.

The correlation of background parenchymal enhancement in the contralateral breast with patient and tumor characteristics of MRI-screen detected breast cancers.

Vreemann S, Gubern-Mérida A, Borelli C, Bult P, Karssemeijer N, Mann RM.

PLoS One. 2018 Jan 19;13(1):e0191399. doi: 10.1371/journal.pone.0191399. eCollection 2018.

9.

Context-aware stacked convolutional neural networks for classification of breast carcinomas in whole-slide histopathology images.

Bejnordi BE, Zuidhof G, Balkenhol M, Hermsen M, Bult P, van Ginneken B, Karssemeijer N, Litjens G, van der Laak J.

J Med Imaging (Bellingham). 2017 Oct;4(4):044504. doi: 10.1117/1.JMI.4.4.044504. Epub 2017 Dec 14.

PMID:
29285517
10.

Diagnostic Assessment of Deep Learning Algorithms for Detection of Lymph Node Metastases in Women With Breast Cancer.

Ehteshami Bejnordi B, Veta M, Johannes van Diest P, van Ginneken B, Karssemeijer N, Litjens G, van der Laak JAWM; the CAMELYON16 Consortium, Hermsen M, Manson QF, Balkenhol M, Geessink O, Stathonikos N, van Dijk MC, Bult P, Beca F, Beck AH, Wang D, Khosla A, Gargeya R, Irshad H, Zhong A, Dou Q, Li Q, Chen H, Lin HJ, Heng PA, Haß C, Bruni E, Wong Q, Halici U, Öner MÜ, Cetin-Atalay R, Berseth M, Khvatkov V, Vylegzhanin A, Kraus O, Shaban M, Rajpoot N, Awan R, Sirinukunwattana K, Qaiser T, Tsang YW, Tellez D, Annuscheit J, Hufnagl P, Valkonen M, Kartasalo K, Latonen L, Ruusuvuori P, Liimatainen K, Albarqouni S, Mungal B, George A, Demirci S, Navab N, Watanabe S, Seno S, Takenaka Y, Matsuda H, Ahmady Phoulady H, Kovalev V, Kalinovsky A, Liauchuk V, Bueno G, Fernandez-Carrobles MM, Serrano I, Deniz O, Racoceanu D, Venâncio R.

JAMA. 2017 Dec 12;318(22):2199-2210. doi: 10.1001/jama.2017.14585.

11.

Influence of Risk Category and Screening Round on the Performance of an MR Imaging and Mammography Screening Program in Carriers of the BRCA Mutation and Other Women at Increased Risk.

Vreemann S, Gubern-Mérida A, Schlooz-Vries MS, Bult P, van Gils CH, Hoogerbrugge N, Karssemeijer N, Mann RM.

Radiology. 2018 Feb;286(2):443-451. doi: 10.1148/radiol.2017170458. Epub 2017 Oct 16.

PMID:
29040037
12.

Discrepancies between biomarkers of primary breast cancer and subsequent brain metastases: an international multicenter study.

Kaidar-Person O, Meattini I, Jain P, Bult P, Simone N, Kindts I, Steffens R, Weltens C, Navarria P, Belkacemi Y, Lopez-Guerra J, Livi L, Baumert BG, Vieites B, Limon D, Kurman N, Ko K, Yu JB, Chiang V, Poortmans P, Zagar T.

Breast Cancer Res Treat. 2018 Jan;167(2):479-483. doi: 10.1007/s10549-017-4526-8. Epub 2017 Oct 3.

PMID:
28975433
13.

Collective invasion in ductal and lobular breast cancer associates with distant metastasis.

Khalil AA, Ilina O, Gritsenko PG, Bult P, Span PN, Friedl P.

Clin Exp Metastasis. 2017 Oct;34(6-7):421-429. doi: 10.1007/s10585-017-9858-6. Epub 2017 Sep 11.

14.

Surveillance of Women with the BRCA1 or BRCA2 Mutation by Using Biannual Automated Breast US, MR Imaging, and Mammography.

van Zelst JCM, Mus RDM, Woldringh G, Rutten MJCM, Bult P, Vreemann S, de Jong M, Karssemeijer N, Hoogerbrugge N, Mann RM.

Radiology. 2017 Nov;285(2):376-388. doi: 10.1148/radiol.2017161218. Epub 2017 Jun 13.

PMID:
28609204
15.

Sonographic Phenotypes of Molecular Subtypes of Invasive Ductal Cancer in Automated 3-D Breast Ultrasound.

van Zelst JCM, Balkenhol M, Tan T, Rutten M, Imhof-Tas M, Bult P, Karssemeijer N, Mann RM.

Ultrasound Med Biol. 2017 Sep;43(9):1820-1828. doi: 10.1016/j.ultrasmedbio.2017.03.019. Epub 2017 May 31.

PMID:
28576620
16.

Cervical metastases originating from a primary rectal adenocarcinoma due to a pagetoid spread.

van der Linden M, Bult P, Nagtegaal ID, Massuger LFAG, de Hullu JA, Bulten J.

Hum Pathol. 2017 Oct;68:184-188. doi: 10.1016/j.humpath.2017.04.017. Epub 2017 Apr 28.

PMID:
28461034
17.

Brief fixation enables same-day breast cancer diagnosis with reliable assessment of hormone receptors, E-cadherin and HER2/Neu.

Halilovic A, Bulte J, Jacobs Y, Braam H, van Cleef P, Schlooz-Vries M, Werner A, Boelens O, Nagtegaal I, de Wilt H, Bult P.

J Clin Pathol. 2017 Sep;70(9):781-786. doi: 10.1136/jclinpath-2017-204362. Epub 2017 Mar 21.

PMID:
28325747
18.

Time to enhancement derived from ultrafast breast MRI as a novel parameter to discriminate benign from malignant breast lesions.

Mus RD, Borelli C, Bult P, Weiland E, Karssemeijer N, Barentsz JO, Gubern-Mérida A, Platel B, Mann RM.

Eur J Radiol. 2017 Apr;89:90-96. doi: 10.1016/j.ejrad.2017.01.020. Epub 2017 Jan 20.

PMID:
28267555
19.

3D volume reconstruction from serial breast specimen radiographs for mapping between histology and 3D whole specimen imaging.

Mertzanidou T, Hipwell JH, Reis S, Hawkes DJ, Ehteshami Bejnordi B, Dalmis M, Vreemann S, Platel B, van der Laak J, Karssemeijer N, Hermsen M, Bult P, Mann R.

Med Phys. 2017 Mar;44(3):935-948. doi: 10.1002/mp.12077.

PMID:
28064435
20.

Deep learning as a tool for increased accuracy and efficiency of histopathological diagnosis.

Litjens G, Sánchez CI, Timofeeva N, Hermsen M, Nagtegaal I, Kovacs I, Hulsbergen-van de Kaa C, Bult P, van Ginneken B, van der Laak J.

Sci Rep. 2016 May 23;6:26286. doi: 10.1038/srep26286.

21.

Automated Detection of DCIS in Whole-Slide H&E Stained Breast Histopathology Images.

Ehteshami Bejnordi B, Balkenhol M, Litjens G, Holland R, Bult P, Karssemeijer N, van der Laak JA.

IEEE Trans Med Imaging. 2016 Sep;35(9):2141-2150. doi: 10.1109/TMI.2016.2550620. Epub 2016 Apr 5.

PMID:
27076354
22.

Methylation biomarkers for pleomorphic lobular breast cancer - a short report.

Moelans CB, Vlug EJ, Ercan C, Bult P, Buerger H, Cserni G, van Diest PJ, Derksen PW.

Cell Oncol (Dordr). 2015 Oct;38(5):397-405. doi: 10.1007/s13402-015-0241-9. Epub 2015 Sep 21.

23.

Erratum to: Quality assessment of estrogen receptor and progesterone receptor testing in breast cancer using a tissue microarray-based approach.

Dekker TJ, ter Borg S, Hooijer GK, Meijer SL, Wesseling J, Boers JE, Schuuring E, Bart J, van Gorp J, Bult P, Riemersma SA, van Deurzen CH, Sleddens HF, Mesker WE, Kroep JR, Smit VT, van de Vijver MJ.

Breast Cancer Res Treat. 2015 Jul;152(2):253. doi: 10.1007/s10549-015-3478-0. No abstract available.

24.

Quality assessment of estrogen receptor and progesterone receptor testing in breast cancer using a tissue microarray-based approach.

Dekker TJ, ter Borg S, Hooijer GK, Meijer SL, Wesseling J, Boers JE, Schuuring E, Bart J, van Gorp J, Bult P, Riemersma SA, van Deurzen CH, Sleddens HF, Mesker WE, Kroep JR, Smit VT, van de Vijver MJ.

Breast Cancer Res Treat. 2015 Jul;152(2):247-52. doi: 10.1007/s10549-015-3444-x. Epub 2015 Jun 4. Erratum in: Breast Cancer Res Treat. 2015 Jul;152(2):253.

25.

Upregulation of IGF-1R expression during neoadjuvant therapy predicts poor outcome in breast cancer patients.

Heskamp S, Boerman OC, Molkenboer-Kuenen JD, Wauters CA, Strobbe LJ, Mandigers CM, Bult P, Oyen WJ, van der Graaf WT, van Laarhoven HW.

PLoS One. 2015 Feb 13;10(2):e0117745. doi: 10.1371/journal.pone.0117745. eCollection 2015.

26.

Brief fixation does not hamper the reliability of Ki67 analysis in breast cancer core-needle biopsies: a double-centre study.

Kalkman S, Bulte JP, Halilovic A, Bult P, van Diest PJ.

Histopathology. 2015 Feb;66(3):380-7. doi: 10.1111/his.12521. Epub 2014 Dec 22.

PMID:
25234295
27.

An alternative way to measure the depth of invasion of vulvar squamous cell carcinoma in relation to prognosis.

van den Einden LC, Massuger LF, Jonkman JK, Bult P, de Hullu JA, Bulten J.

Mod Pathol. 2015 Feb;28(2):295-302. doi: 10.1038/modpathol.2014.103. Epub 2014 Sep 5.

28.

HNF4A immunohistochemistry facilitates distinction between primary and metastatic breast and gastric carcinoma.

van der Post RS, Bult P, Vogelaar IP, Ligtenberg MJ, Hoogerbrugge N, van Krieken JH.

Virchows Arch. 2014 Jun;464(6):673-9. doi: 10.1007/s00428-014-1574-x. Epub 2014 Apr 8.

PMID:
24711169
29.

Germline MUTYH gene mutations are not frequently found in unselected patients with papillary breast carcinoma.

Boesaard EP, Vogelaar IP, Bult P, Wauters CA, van Krieken JH, Ligtenberg MJ, van der Post RS, Hoogerbrugge N.

Hered Cancer Clin Pract. 2014 Dec 12;12(1):21. doi: 10.1186/1897-4287-12-21. eCollection 2014.

30.

Models predicting non-sentinel node involvement also predict for regional recurrence in breast cancer patients without axillary treatment.

Pepels MJ, Vestjens JH, de Boer M, Bult P, Van Dijck JA, Menke-Pluijmers M, van Diest PJ, Borm G, Tjan-Heijnen VC.

Eur J Surg Oncol. 2013 Dec;39(12):1351-7. doi: 10.1016/j.ejso.2013.09.006. Epub 2013 Oct 2.

PMID:
24135686
31.

Nuclear localization of the transcriptional coactivator YAP is associated with invasive lobular breast cancer.

Vlug EJ, van de Ven RA, Vermeulen JF, Bult P, van Diest PJ, Derksen PW.

Cell Oncol (Dordr). 2013 Oct;36(5):375-84. doi: 10.1007/s13402-013-0143-7. Epub 2013 Aug 15.

32.

Breast cancer size estimation with MRI in BRCA mutation carriers and other high risk patients.

Mann RM, Bult P, van Laarhoven HW, Span PN, Schlooz M, Veltman J, Hoogerbrugge N.

Eur J Radiol. 2013 Sep;82(9):1416-22. doi: 10.1016/j.ejrad.2013.03.003. Epub 2013 Apr 6.

PMID:
23567481
33.

Is the sentinel lymph node pathology protocol in breast cancer patients associated with the risk of regional recurrence?

Bolster MJ, Pepels MJ, Wauters CA, Schapers RF, Meijer JW, Strobbe LJ, van Berlo CL, Klinkenbijl JH, Wobbes T, Voogd AC, Bult P, Tjan-Heijnen VC.

Eur J Surg Oncol. 2013 May;39(5):437-41. doi: 10.1016/j.ejso.2013.02.013. Epub 2013 Feb 23.

34.

Interobserver variability and the effect of education in the histopathological diagnosis of differentiated vulvar intraepithelial neoplasia.

van den Einden LC, de Hullu JA, Massuger LF, Grefte JM, Bult P, Wiersma A, van Engen-van Grunsven AC, Sturm B, Bosch SL, Hollema H, Bulten J.

Mod Pathol. 2013 Jun;26(6):874-80. doi: 10.1038/modpathol.2012.235. Epub 2013 Feb 1.

35.

One-day core needle biopsy in a breast clinic: 4 years experience.

Bulte JP, Polman L, Schlooz-Vries M, Werner A, Besselink R, Sessink K, Mus R, Lardenoije S, Imhof-Tas M, Bulten J, van Engen-van Grunsven AC, Schaafsma E, Strobbe LJ, Bult P, De Wilt JH.

Breast Cancer Res Treat. 2013 Jan;137(2):609-16. doi: 10.1007/s10549-012-2372-2. Epub 2012 Dec 14.

PMID:
23239152
36.

HIF-1α and NOTCH signaling in ductal and lobular carcinomas of the breast.

Ercan C, Vermeulen JF, Hoefnagel L, Bult P, van der Groep P, van der Wall E, van Diest PJ.

Cell Oncol (Dordr). 2012 Dec;35(6):435-42. doi: 10.1007/s13402-012-0102-8. Epub 2012 Sep 25.

PMID:
23008060
37.

Higher cytoplasmic and nuclear poly(ADP-ribose) polymerase expression in familial than in sporadic breast cancer.

Klauke ML, Hoogerbrugge N, Budczies J, Bult P, Prinzler J, Radke C, van Krieken JH, Dietel M, Denkert C, Müller BM.

Virchows Arch. 2012 Oct;461(4):425-31. doi: 10.1007/s00428-012-1311-2. Epub 2012 Sep 12.

PMID:
22968923
38.

TRPM7 is required for breast tumor cell metastasis.

Middelbeek J, Kuipers AJ, Henneman L, Visser D, Eidhof I, van Horssen R, Wieringa B, Canisius SV, Zwart W, Wessels LF, Sweep FC, Bult P, Span PN, van Leeuwen FN, Jalink K.

Cancer Res. 2012 Aug 15;72(16):4250-61. Epub 2012 Aug 7.

39.

Immunophenotyping invasive breast cancer: paving the road for molecular imaging.

Vermeulen JF, van Brussel AS, van der Groep P, Morsink FH, Bult P, van der Wall E, van Diest PJ.

BMC Cancer. 2012 Jun 13;12:240. doi: 10.1186/1471-2407-12-240.

40.

Nuclear Kaiso expression is associated with high grade and triple-negative invasive breast cancer.

Vermeulen JF, van de Ven RA, Ercan C, van der Groep P, van der Wall E, Bult P, Christgen M, Lehmann U, Daniel J, van Diest PJ, Derksen PW.

PLoS One. 2012;7(5):e37864. doi: 10.1371/journal.pone.0037864. Epub 2012 May 25.

41.

Relevant impact of central pathology review on nodal classification in individual breast cancer patients.

Vestjens JH, Pepels MJ, de Boer M, Borm GF, van Deurzen CH, van Diest PJ, van Dijck JA, Adang EM, Nortier JW, Rutgers EJ, Seynaeve C, Menke-Pluymers MB, Bult P, Tjan-Heijnen VC.

Ann Oncol. 2012 Oct;23(10):2561-6. Epub 2012 Apr 11.

PMID:
22495317
42.

Cost-effectiveness of adjuvant systemic therapy in low-risk breast cancer patients with nodal isolated tumor cells or micrometastases.

de Boer M, Adang EM, Van Dycke KC, van Dijck JA, Borm GF, Seferina SC, van Deurzen CH, van Diest PJ, Bult P, Donders AR, Tjan-Heijnen VC.

Ann Oncol. 2012 Oct;23(10):2585-91. Epub 2012 Mar 26.

PMID:
22449731
43.

p53 mutations in classic and pleomorphic invasive lobular carcinoma of the breast.

Ercan C, van Diest PJ, van der Ende B, Hinrichs J, Bult P, Buerger H, van der Wall E, Derksen PW.

Cell Oncol (Dordr). 2012 Apr;35(2):111-8. doi: 10.1007/s13402-012-0071-y. Epub 2012 Feb 22.

44.

Regional recurrence in breast cancer patients with sentinel node micrometastases and isolated tumor cells.

Pepels MJ, de Boer M, Bult P, van Dijck JA, van Deurzen CH, Menke-Pluymers MB, van Diest PJ, Borm GF, Tjan-Heijnen VC.

Ann Surg. 2012 Jan;255(1):116-21. doi: 10.1097/SLA.0b013e31823dc616.

PMID:
22183034
45.

Prognostic impact of isolated tumor cells in breast cancer axillary nodes: single tumor cell(s) versus tumor cell cluster(s) and microanatomic location.

Vestjens JH, de Boer M, van Diest PJ, van Deurzen CH, van Dijck JA, Borm GF, Adang EM, Bult P, Tjan-Heijnen VC.

Breast Cancer Res Treat. 2012 Jan;131(2):645-51. doi: 10.1007/s10549-011-1771-0. Epub 2011 Sep 17.

PMID:
21927853
46.

Angiosarcoma in a patient with immunodeficiency, centromeric region instability, facial anomalies (ICF) syndrome.

van den Brand M, Flucke UE, Bult P, Weemaes CM, van Deuren M.

Am J Med Genet A. 2011 Mar;155A(3):622-5. doi: 10.1002/ajmg.a.33831. Epub 2011 Feb 18.

PMID:
21337690
47.

Fatal thrombotic microangiopathy after a single dose of gemcitabine as fourth-line palliative treatment for metastasized ductal breast carcinoma.

Willemsen AE, van Herpen CM, Wesseling P, Bult P, van Laarhoven HW.

Acta Oncol. 2011 Apr;50(3):462-5. doi: 10.3109/0284186X.2010.491088. Epub 2010 Aug 30. No abstract available.

PMID:
20799915
48.

Breast cancer prognosis and occult lymph node metastases, isolated tumor cells, and micrometastases.

de Boer M, van Dijck JA, Bult P, Borm GF, Tjan-Heijnen VC.

J Natl Cancer Inst. 2010 Mar 17;102(6):410-25. doi: 10.1093/jnci/djq008. Epub 2010 Feb 26. Review.

PMID:
20190185
49.

DC-SCRIPT: nuclear receptor modulation and prognostic significance in primary breast cancer.

Ansems M, Hontelez S, Looman MW, Karthaus N, Bult P, Bonenkamp JJ, Jansen JH, Sweep FC, Span PN, Adema GJ.

J Natl Cancer Inst. 2010 Jan 6;102(1):54-68. doi: 10.1093/jnci/djp441. Epub 2009 Dec 14.

PMID:
20008677
50.

The impact of preoperative breast MRI on the re-excision rate in invasive lobular carcinoma of the breast.

Mann RM, Loo CE, Wobbes T, Bult P, Barentsz JO, Gilhuijs KG, Boetes C.

Breast Cancer Res Treat. 2010 Jan;119(2):415-22. doi: 10.1007/s10549-009-0616-6.

PMID:
19885731

Supplemental Content

Support Center